Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | LDHA | P00338 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | LDHB | P07195 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL262024 | 1.00 | — | — | |
| Bicarbonate SCHEMBL27852410 | 0.94 | — | — | |
| Bicarbonate SCHEMBL27415811 | 0.94 | — | — | |
| Bicarbonate SCHEMBL28329356 | 0.94 | — | — | |
| Bicarbonate SCHEMBL11671968 | 0.94 | — | — | |
| Bicarbonate SCHEMBL27869306 | 0.94 | — | — | |
| Bicarbonate SCHEMBL6013375 | 0.94 | — | — | |
| Bicarbonate SCHEMBL4306718 | 0.94 | — | — | |
| Bicarbonate SCHEMBL3995099 | 0.93 | CA1 (0.83) | CA1CA2CA9FFAR3ACHE | |
| Bicarbonate SCHEMBL8209384 | 0.93 | CA1 (0.83) | CA1CA2CA9FFAR3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108314634-A | The method that taurine is prepared by alkali metal isethionate salt and vinyl sulfonic acid alkali metal salt cycle | 维生源知识产权有限责任公司 | 2018-07-24 | — | — | CN | claimed |
| US-7081465-B2 | Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-25 | — | — | US | claimed |
| EP-0905576-A1 | Charging device | XEROX CORPORATION (US) | 1999-03-31 | — | — | EP | claimed |
| CN-116768250-A | Spodumene treatment method and device | 广西中伟新材料科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-110560015-A | nano hydrated oxidized metal composite hydrogel and application of nano hydrated oxidized metal composite hydrogel in sewage treatment | 魏旭榕 | 2019-12-13 | — | — | CN | disclosed |
| WO-2012046251-A2 | NOVEL FORM OF RANELIC ACID | GLENMARK GENERICS LIMITED (IN) | 2012-04-12 | — | — | WO | disclosed |
| CN-101652716-A | Photosensitive resin composition, photosensitive film, method for forming pattern by using the photosensitive film, and printed board | FUJIFILM CORP JP | 2010-02-17 | — | — | CN | disclosed |
| US-20090281146-A1 | PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-11-12 | — | — | US | disclosed |
| US-7563900-B2 | Process for the preparation N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-07-21 | — | — | US | disclosed |
| US-7470786-B2 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2008-12-30 | — | — | US | disclosed |
| EP-1799632-A2 | PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE | Glenmark Pharmaceuticals S.A. (CH) | 2007-06-27 | — | — | EP | disclosed |
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-03-01 | — | — | US | disclosed |
| US-20060135779-A1 | Process for the preparation n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide | GLENMARK PHARMACEUTICALS S.A. (CH) | 2006-06-22 | — | — | US | disclosed |
| WO-2006040652-A2 | PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-0763032-B1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO INC (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-0905576-A1 | Charging device | XEROX CORPORATION (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0763032-A1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO. INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5567824-A | CATALYZING THE CYCLIZATION IN PRESENCE OF A SOLVENT AND A PROTON ACCEPTOR | MERCK & CO., INC. (US) | 1996-10-22 | — | — | US | disclosed |
| WO-1995032197-A1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO., INC. (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135779-A1 | Process for the preparation n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide | HCN4, REN, QDPR | CA1 454/4885CA2 75/4885CA9 186/4885 |
| US-20090281146-A1 | PROCESS FOR THE PREPARATION OF N-(3,5-DICHLOROPYRID-4-YL)-4-DIFLUOROMETHOXY-8-METHANESULFONAMIDO-DIBENZO[B,D]FURAN-1-CARBOXAMIDE | DHODH, QDPR, DPYD | CA1 455/4885CA2 36/4885CA9 138/4885 |
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | CA1 1613/4885CA2 1218/4885CA9 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.